A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Latest Information Update: 19 Feb 2025
At a glance
- Drugs Ipilimumab (Primary) ; T cell replacement therapy (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders
- Focus Adverse reactions
Most Recent Events
- 10 Jun 2024 Planned End Date changed from 25 May 2025 to 1 Jul 2024.
- 10 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 26 May 2023 Planned End Date changed from 31 May 2025 to 25 May 2025.